🇺🇸 LAZERTINIB in United States

118 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Rash — 27 reports (22.88%)
  2. Neuropathy Peripheral — 25 reports (21.19%)
  3. Off Label Use — 12 reports (10.17%)
  4. Paronychia — 10 reports (8.47%)
  5. Diarrhoea — 8 reports (6.78%)
  6. Pruritus — 8 reports (6.78%)
  7. Anal Ulcer — 7 reports (5.93%)
  8. Dermatitis Acneiform — 7 reports (5.93%)
  9. Drug Eruption — 7 reports (5.93%)
  10. Hypoaesthesia — 7 reports (5.93%)

Source database →

LAZERTINIB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is LAZERTINIB approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for LAZERTINIB in United States?

Marketing authorisation holder not available in our data.